Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANDY-CRASH
2022-501500-10-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Sud Francilien
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial comparing Sufenta arm with Ultiva arm (2 arms). Primary endpoint: Absolute variation of heart rate between T0 and T2. Planned start Nov 2022; status: authorised.
02
Drugs
sufentanilremifentanil
Beyond the preview
Go deeper on 2022-501500-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501500-10-00.